Denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women: A randomized, double-blind, placebo-controlled, multicenter phase III study
Jiemei Gu,Hao Zhang,Qingyun Xue,Li Wang,Zhifeng Cheng,Yawei Zhang,Qifu Li,Lingqing Yuan,Yukun Li,Jin Dong,Yanan Huo,Xin Tang,Ling Hu,Xinjia Wang,Fei Hua,Lin Shen,Jinluo Cheng,Huimin Zhou,Youjia Xu,Tao Yang,Chuansuo Wang,Jin Xu,Jie Shen,Ying Zhang,Xiaomei Zhang,Dun Hong,Xiaoling Guan,Xinhua Xiao,Guang Wang,Yonghua Liu,Liujun Fu,Jianting Chen,Xigao Cheng,Yue Ding,Lijun Liu,Qi Yao,Xinchao Zhang,Lixin Li,Panjun Zhang,Chunying Deng,Chengyan Jiang,Li You,Kai Wang,Shimin Zhang,Jianzhong Xiao,Wei Liu,Xiaohong Du,Xianwen Shang,Tianrong Pan,Chen Lei,Shuren Guo,Zhenlin Zhang
DOI: https://doi.org/10.1016/j.jot.2022.06.007
IF: 6.6
2023-01-01
Journal of Orthopaedic Translation
Abstract:Objectives: This study assessed the efficacy, safety, pharmacokinetics (PK), and immunogenicity profiles of a denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women with a high risk of fracture.Methods: In this multicenter, randomized, double-blind, placebo-controlled, phase 3 trial, 448 postmenopausal women aged 50-85 years with osteoporosis were enrolled at 49 centers in China and were randomly assigned (3:1) to receive 60 mg of the denosumab biosimilar (LY06006) or placebo subcutaneously every 6 months for 1 year. Lumbar spine bone mineral density (BMD) change was the primary endpoint.Results: Of the 448 randomized patients, 409 (LY06006, n = 311; placebo, n = 98) completed the study. All 448 (100.0%) subjects were included in the intent-to-treat (ITT) trial, 427 (95.3%) were included in the full analysis set (FAS), 408 (91.1%) were included in the per protocol set (PPS), 446 (99.6%) were included in the safety set (SS), and 336 (75.0%) were included in the pharmacokinetics concentration set (PKCs). For the primary endpoint, a 4.71% (95% CI, 3.81%, 5.60%) treatment difference in percent change in lumbar spine BMD from baseline to month 12 was observed in the LY06006 group compared with the placebo group (P < 0.0001). For the secondary endpoints, LY06006 was associated with increased lumbar spine BMD levels measured at month 6, BMD levels at the femoral neck, total hip, and trochanter measured at months 6 and 12 and reduced serum C-terminal telopeptide of type 1 collagen (CTX) and procollagen type 1 N-peptide (P1NP) levels at months 1, 6, and 12. Safety analysis was based on the safety analysis set (SS), and 264 (78.6%) subjects in the LY06006 group and 83 (75.5%) in the placebo group experienced adverse events (AEs). Most events were mild or moderate and not related to the study drugs.Conclusion: In postmenopausal women with a high risk of fracture, LY06006 increased the BMD and decreased bone resorption; thus, LY06006 might be an effective treatment for osteoporosis. LY06006 was generally safe and well tolerated without unexpected adverse reactions, similar to the reference drug Prolia®. The characteristics of effectiveness and safety were similar to those reported in previous studies.The translational potential of this article: In this multi-center, randomized, double-blind, placebo-controlled phase 3 study, LY06006 showed substantially efficacy to increase BMD and well tolerance without unexpected adverse reactions, which is comparable to the reference drug Prolia ®. The presented results are encouraging and can offer some valuable evidence for the clinical practice.
orthopedics